- Home
- FCFS vs RYTM Comparison
FCFS vs RYTM Comparison
Compare FCFS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- RYTM
- Stock Information
- Founded
- FCFS 1988
- RYTM 2008
- Country
- FCFS United States
- RYTM United States
- Employees
- FCFS N/A
- RYTM 283
- Industry
- FCFS Other Specialty Stores
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- RYTM Health Care
- Exchange
- FCFS Nasdaq
- RYTM Nasdaq
- Market Cap
- FCFS 6.5B
- RYTM 6.9B
- IPO Year
- FCFS 1991
- RYTM 2017
- Fundamental
- Price
- FCFS $147.13
- RYTM $102.12
- Analyst Decision
- FCFS Buy
- RYTM Strong Buy
- Analyst Count
- FCFS 3
- RYTM 13
- Target Price
- FCFS $137.33
- RYTM $101.92
- AVG Volume (30 Days)
- FCFS 283.3K
- RYTM 550.8K
- Earning Date
- FCFS 10-23-2025
- RYTM 11-04-2025
- Dividend Yield
- FCFS 1.14%
- RYTM N/A
- EPS Growth
- FCFS 24.22
- RYTM N/A
- EPS
- FCFS 6.50
- RYTM N/A
- Revenue
- FCFS $3,388,177,000.00
- RYTM $156,287,000.00
- Revenue This Year
- FCFS $3.73
- RYTM $44.69
- Revenue Next Year
- FCFS $8.14
- RYTM $63.53
- P/E Ratio
- FCFS $22.70
- RYTM N/A
- Revenue Growth
- FCFS 2.49
- RYTM 53.55
- 52 Week Low
- FCFS $100.24
- RYTM $45.91
- 52 Week High
- FCFS $150.92
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- FCFS 61.61
- RYTM 60.62
- Support Level
- FCFS $145.04
- RYTM $101.45
- Resistance Level
- FCFS $150.92
- RYTM $106.52
- Average True Range (ATR)
- FCFS 2.83
- RYTM 3.12
- MACD
- FCFS 0.37
- RYTM -0.43
- Stochastic Oscillator
- FCFS 73.84
- RYTM 65.84
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.